INO
Price
$0.99
Change
-$0.05 (-4.81%)
Updated
Oct 16 closing price
Capitalization
120.98M
24 days until earnings call
Intraday BUY SELL Signals
LPCN
Price
$1.56
Change
-$0.12 (-7.14%)
Updated
Oct 16 closing price
Capitalization
17.23M
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs LPCN

INO vs LPCN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
INO vs. LPCN commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and LPCN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for INO with price predictions
Oct 16, 2026

INO sees MACD Histogram crosses below signal line

INO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 37 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 66 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

INO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for INO entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 183 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.701) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LPCN with price predictions
Oct 16, 2026

LPCN sees MACD Histogram crosses below signal line

LPCN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 15, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 36 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LPCN as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

LPCN moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LPCN crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for LPCN entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where LPCN advanced for three days, in 213 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

LPCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.792) is normal, around the industry mean (26.782). P/E Ratio (7.686) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (9.302) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
INO vs LPCN: Fundamental Ratings
INO
LPCN
OUTLOOK RATING
1..100
6596
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
7684
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
3150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (57) in the Pharmaceuticals Other industry is in the same range as INO (79) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.

LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.

LPCN's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.

INO's Price Growth Rating (76) in the Medical Specialties industry is in the same range as LPCN (84) in the Pharmaceuticals Other industry. This means that INO’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's P/E Growth Rating (95) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOLPCN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 30 days ago
79%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (INO: $0.99 vs. LPCN: $1.56)
Brand notoriety: INO: Notable vs. LPCN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 66% vs. LPCN: 55%
Market capitalization -- INO: $120.98M vs. LPCN: $17.23M
INO [@Biotechnology] is valued at $120.98M. LPCN’s [@Biotechnology] market capitalization is $17.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green while LPCN’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, LPCN is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 3 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).

  • INO’s TA Score: 3 bullish, 6 bearish.
  • LPCN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, LPCN is a better buy in the short-term than INO.

Price Growth

INO (@Biotechnology) experienced а -13.90% price change this week, while LPCN (@Biotechnology) price change was -9.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

INO is expected to report earnings on Nov 10, 2026.

LPCN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
INO
Daily Signal:
Gain/Loss:
LPCN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EPR55.710.56
+1.02%
EPR Properties
TRST54.310.29
+0.54%
TrustCo Bank Corp
DHI139.39-0.16
-0.11%
DR Horton
UONEK3.66-0.02
-0.54%
Urban One Inc.
LCUT8.13-0.66
-7.51%
Lifetime Brands

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-4.80%
AXON - INO
53%
Loosely correlated
-6.45%
ARRY - INO
52%
Loosely correlated
-3.92%
ALNY - INO
45%
Loosely correlated
-0.94%
LPCN - INO
41%
Loosely correlated
-7.14%
AMRN - INO
39%
Loosely correlated
-2.16%
More

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
-7.14%
SPRY - LPCN
63%
Loosely correlated
-1.23%
HYFT - LPCN
43%
Loosely correlated
-6.43%
ELAB - LPCN
41%
Loosely correlated
-7.51%
INO - LPCN
41%
Loosely correlated
-4.80%
ZNTL - LPCN
36%
Loosely correlated
-4.91%
More